Form 8-K - Current report:
SEC Accession No. 0000950170-22-005307
Filing Date
2022-04-04
Accepted
2022-04-04 08:35:50
Documents
13
Period of Report
2022-04-01
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K rlyb-20220401.htm   iXBRL 8-K 62115
2 EX-99.1 rlyb-ex99_1.htm EX-99.1 25252
  Complete submission text file 0000950170-22-005307.txt   216318

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT rlyb-20220401_lab.xml EX-101.LAB 13996
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT rlyb-20220401_pre.xml EX-101.PRE 11459
5 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT rlyb-20220401.xsd EX-101.SCH 2478
7 EXTRACTED XBRL INSTANCE DOCUMENT rlyb-20220401_htm.xml XML 4886
Mailing Address 234 CHURCH STREET SUITE 1020 NEW HAVEN CT 06510
Business Address 234 CHURCH STREET SUITE 1020 NEW HAVEN CT 06510 203- 859-3820
Rallybio Corp (Filer) CIK: 0001739410 (see all company filings)

EIN.: 851083789 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40693 | Film No.: 22800458
SIC: 2834 Pharmaceutical Preparations